Observational, prospective, multicenter study. Collection of data relating to the effectiveness of sacituzumab govitecan SG, in a real-world context and planned research of predictive biomarkers of efficacy/tolerability carried out on multiple platforms at the center coordinator.
Age ≥ 18 years;
Histological diagnosis of TNBC;
Locally advanced unresectable or metastatic disease;
Indication for treatment with SG in monotherapy according to clinical practice (patients pre-treated with at least two lines of systemic therapy, of which at least one in an advanced stage);
Patients with a history of other malignancies;
Contraindications to the use of sacituzumab govitecan SG;
Untreated and/or clinically unstable (symptomatic) brain metastases.
Regina Elena Cancer Institute
Lead sponsor
Ospedale Sandro Pertini, Roma
Collaborator
Catholic University of the Sacred Heart
Collaborator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborator
Campus Bio-Medico University
Collaborator
Azienda Policlinico Umberto I
Collaborator
San Giovanni Addolorata Hospital
Collaborator
Ospedale "SS Annunziata", Chieti
Collaborator
Ospedale "Gaetano Bernabeo" , Ortona
Collaborator
Hospital San Pietro Fatebenefratelli
Collaborator
presidio Ospedaliero santo spirito in Sassia, Roma
Collaborator
Ospedale di Belcolle - Viterbo
Collaborator